Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Déas O[au]:

Search results

Items: 27

1.

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.

Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutiérrez-Enríquez S, Ducy M, Ibrahim YH, Gris-Oliver A, Pellegrino B, Bruna A, Guzmán M, Rodríguez O, Grueso J, Bonache S, Moles-Fernández A, Villacampa G, Viaplana C, Gómez P, Vidal M, Peg V, Serres-Créixams X, Dellaire G, Simard J, Nuciforo P, Rubio IT, Dientsmann R, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Déas O, Jonkers J, Masson JY, Cairo S, Judde JG, O'Connor MJ, Díez O, Balmaña J, Serra V.

EMBO Mol Med. 2018 Oct 30. pii: e9172. doi: 10.15252/emmm.201809172. [Epub ahead of print]

2.

MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab.

Cataldo A, Piovan C, Plantamura I, D'Ippolito E, Camelliti S, Casalini P, Giussani M, Déas O, Cairo S, Judde JG, Tagliabue E, Iorio MV.

Oncotarget. 2018 Jun 15;9(46):27920-27928. doi: 10.18632/oncotarget.24723. eCollection 2018 Jun 15.

3.

An NF90/NF110-mediated feedback amplification loop regulates dicer expression and controls ovarian carcinoma progression.

Barbier J, Chen X, Sanchez G, Cai M, Helsmoortel M, Higuchi T, Giraud P, Contreras X, Yuan G, Feng Z, Nait-Saidi R, Deas O, Bluy L, Judde JG, Rouquier S, Ritchie W, Sakamoto S, Xie D, Kiernan R.

Cell Res. 2018 May;28(5):556-571. doi: 10.1038/s41422-018-0016-8. Epub 2018 Mar 21.

4.

Murine model of hepatic breast cancer.

Rikhi R, Wilson EM, Deas O, Svalina MN, Bial J, Mansoor A, Cairo S, Keller C.

Biochem Biophys Rep. 2016 Aug 4;8:1-5. doi: 10.1016/j.bbrep.2016.07.021. eCollection 2016 Dec.

5.

Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer.

Formisano L, Stauffer KM, Young CD, Bhola NE, Guerrero-Zotano AL, Jansen VM, Estrada MM, Hutchinson KE, Giltnane JM, Schwarz LJ, Lu Y, Balko JM, Deas O, Cairo S, Judde JG, Mayer IA, Sanders M, Dugger TC, Bianco R, Stricker T, Arteaga CL.

Clin Cancer Res. 2017 Oct 15;23(20):6138-6150. doi: 10.1158/1078-0432.CCR-17-1232. Epub 2017 Jul 27.

6.

Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents.

Gaston J, Cheradame L, Yvonnet V, Deas O, Poupon MF, Judde JG, Cairo S, Goffin V.

Oncotarget. 2016 Nov 22;7(47):77205-77224. doi: 10.18632/oncotarget.12858.

7.

Patient-derived mouse xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management.

Nicolle D, Fabre M, Simon-Coma M, Gorse A, Kappler R, Nonell L, Mallo M, Haidar H, Déas O, Mussini C, Guettier C, Redon MJ, Brugières L, Ghigna MR, Fadel E, Galmiche-Rolland L, Chardot C, Judde JG, Armengol C, Branchereau S, Cairo S.

Hepatology. 2016 Oct;64(4):1121-35. doi: 10.1002/hep.28621. Epub 2016 Jun 16.

PMID:
27115099
8.

Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer.

Legrier ME, Bièche I, Gaston J, Beurdeley A, Yvonnet V, Déas O, Thuleau A, Château-Joubert S, Servely JL, Vacher S, Lassalle M, Depil S, Tucker GC, Fontaine JJ, Poupon MF, Roman-Roman S, Judde JG, Decaudin D, Cairo S, Marangoni E.

Br J Cancer. 2016 Jan 19;114(2):177-87. doi: 10.1038/bjc.2015.398. Epub 2015 Dec 22.

9.

The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features.

Aloia A, Petrova E, Tomiuk S, Bissels U, Déas O, Saini M, Zickgraf FM, Wagner S, Spaich S, Sütterlin M, Schneeweiss A, Reitberger M, Rüberg S, Gerstmayer B, Agorku D, Knöbel S, Terranegra A, Falleni M, Soldati L, Sprick MR, Trumpp A, Judde JG, Bosio A, Cairo S, Hardt O.

Breast Cancer Res. 2015 Nov 25;17(1):146. doi: 10.1186/s13058-015-0652-6.

10.

The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.

Schuller AG, Barry ER, Jones RD, Henry RE, Frigault MM, Beran G, Linsenmayer D, Hattersley M, Smith A, Wilson J, Cairo S, Déas O, Nicolle D, Adam A, Zinda M, Reimer C, Fawell SE, Clark EA, D'Cruz CM.

Clin Cancer Res. 2015 Jun 15;21(12):2811-9. doi: 10.1158/1078-0432.CCR-14-2685. Epub 2015 Mar 16.

11.

NOTCH1 nuclear interactome reveals key regulators of its transcriptional activity and oncogenic function.

Yatim A, Benne C, Sobhian B, Laurent-Chabalier S, Deas O, Judde JG, Lelievre JD, Levy Y, Benkirane M.

Mol Cell. 2012 Nov 9;48(3):445-58. doi: 10.1016/j.molcel.2012.08.022. Epub 2012 Sep 27.

12.

A flavivirus protein M-derived peptide directly permeabilizes mitochondrial membranes, triggers cell death and reduces human tumor growth in nude mice.

Brabant M, Baux L, Casimir R, Briand JP, Chaloin O, Porceddu M, Buron N, Chauvier D, Lassalle M, Lecoeur H, Langonné A, Dupont S, Déas O, Brenner C, Rebouillat D, Muller S, Borgne-Sanchez A, Jacotot E.

Apoptosis. 2009 Oct;14(10):1190-203. doi: 10.1007/s10495-009-0394-y.

PMID:
19693674
13.

Targeted Vpr-derived peptides reach mitochondria to induce apoptosis of alphaVbeta3-expressing endothelial cells.

Borgne-Sanchez A, Dupont S, Langonné A, Baux L, Lecoeur H, Chauvier D, Lassalle M, Déas O, Brière JJ, Brabant M, Roux P, Péchoux C, Briand JP, Hoebeke J, Deniaud A, Brenner C, Rustin P, Edelman L, Rebouillat D, Jacotot E.

Cell Death Differ. 2007 Mar;14(3):422-35. Epub 2006 Aug 4.

14.

In vivo gene targeting of IL-3 into immature hematopoietic cells through CD117 receptor mediated antibody gene delivery.

Chapel A, Deas O, Bensidhoum M, François S, Mouiseddine M, Poncet P, Dürrbach A, Aigueperse J, Gourmelon P, Gorin NC, Hirsch F, Thierry D.

Genet Vaccines Ther. 2004 Oct 27;2:16. doi: 10.1186/1479-0556-2-16. eCollection 2004.

15.

Potentiation of tumour apoptosis by human growth hormone via glutathione production and decreased NF-kappaB activity.

Cherbonnier C, Déas O, Carvalho G, Vassal G, Dürrbach A, Haeffner A, Charpentier B, Bénard J, Hirsch F.

Br J Cancer. 2003 Sep 15;89(6):1108-15.

16.

In vivo-targeted gene delivery using antibody-based nonviral vector.

Déas O, Angevin E, Cherbonnier C, Senik A, Charpentier B, Levillain JP, Oosterwijk E, Hirsch F, Dürrbach A.

Hum Gene Ther. 2002 Jun 10;13(9):1101-14.

PMID:
12067443
17.

Human growth hormone gene transfer into tumor cells may improve cancer chemotherapy.

Cherbonnier C, Déas O, Vassal G, Merlin JL, Haeffner A, Senik A, Charpentier B, Dürrbach A, Bénard J, Hirsch F.

Cancer Gene Ther. 2002 Jun;9(6):497-504.

18.

Targeting additional costimulatory pathways: a subtle role for CD2.

Dumont C, Deas O, Hebib C, Durrbach A, Hirsch F, Charpentier B, Senik A.

Transplant Proc. 2001 Feb-Mar;33(1-2):199-200. No abstract available.

PMID:
11266778
20.

Effects of anti-CD2 monoclonal antibody: CD2- and CD95-mediated apoptosis of human peripheral T cells.

Mollereau B, Deas O, Dumont C, Charpentier B, Senik A.

Transplant Proc. 1999 Feb-Mar;31(1-2):1245. No abstract available.

PMID:
10083556
21.

Growth hormone prevents human monocytic cells from Fas-mediated apoptosis by up-regulating Bcl-2 expression.

Haeffner A, Déas O, Mollereau B, Estaquier J, Mignon A, Haeffner-Cavaillon N, Charpentier B, Senik A, Hirsch F.

Eur J Immunol. 1999 Jan;29(1):334-44.

22.

Caspase-independent cell death induced by anti-CD2 or staurosporine in activated human peripheral T lymphocytes.

Déas O, Dumont C, MacFarlane M, Rouleau M, Hebib C, Harper F, Hirsch F, Charpentier B, Cohen GM, Senik A.

J Immunol. 1998 Oct 1;161(7):3375-83.

23.

Potent apoptotic signaling and subsequent unresponsiveness induced by a single CD2 mAb (BTI-322) in activated human peripheral T cells.

Dumont C, Déas O, Mollereau B, Hebib C, Giovino-Barry V, Bernard A, Hirsch F, Charpentier B, Senik A.

J Immunol. 1998 Apr 15;160(8):3797-804.

24.
25.

Inhibitory effect of growth hormone on TNF-alpha secretion and nuclear factor-kappaB translocation in lipopolysaccharide-stimulated human monocytes.

Haeffner A, Thieblemont N, Déas O, Marelli O, Charpentier B, Senik A, Wright SD, Haeffner-Cavaillon N, Hirsch F.

J Immunol. 1997 Feb 1;158(3):1310-4.

PMID:
9013974
26.

Thiol-mediated inhibition of FAS and CD2 apoptotic signaling in activated human peripheral T cells.

Déas O, Dumont C, Mollereau B, Métivier D, Pasquier C, Bernard-Pomier G, Hirsch F, Charpentier B, Senik A.

Int Immunol. 1997 Jan;9(1):117-25.

PMID:
9043953
27.

CD2-induced apoptosis in activated human peripheral T cells: a Fas-independent pathway that requires early protein tyrosine phosphorylation.

Mollereau B, Deckert M, Déas O, Rieux-Laucat F, Hirsch F, Bernard A, Fischer A, Lynch DH, Charpentier B, Le Deist F, Senik A.

J Immunol. 1996 May 1;156(9):3184-90.

PMID:
8617939

Supplemental Content

Support Center